Scarica l'app Stockscreener
1.43
9.16%
0.12
Precedente Chiudi:
$1.31
Aprire:
$1.29
Volume 24 ore:
470.23K
Relative Volume:
0.33
Capitalizzazione di mercato:
$6.85M
Reddito:
-
Utile/perdita netta:
$-27.39M
Rapporto P/E:
-0.851
EPS:
-1.6803
Flusso di cassa netto:
$-2.09M
1 W Prestazione:
-2.05%
1M Prestazione:
-55.20%
6M Prestazione:
-91.04%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.2857
$1.50
Intervallo di 1 settimana:
$1.20
$1.50
Portata 52W:
$1.20
$84.00
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Nome
Aspire Biopharma Holdings Inc
Settore
Industria
Telefono
561-704-8527
Indirizzo
23150 FASHION DRIVE, SUITE 232, ESTERO
Compare ASBP vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
1.43 | 6.27M | 0 | -27.39M | -2.09M | -1.6803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Aspire Biopharma Holdings Inc Borsa (ASBP) Ultime notizie
Aspire Biopharma secures up to $21M in convertible preferred stock financing - MSN
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - Palm Beach Daily News
Aspire Biopharma appoints Phillip Balatsos to board of directors By Investing.com - Investing.com Nigeria
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Springfield News-Leader
Aspire Biopharma appoints Phillip Balatsos to board of directors - Investing.com
Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors - itemonline.com
Veteran markets executive joins Aspire to push rapid-onset drug platform - Stock Titan
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity - Worcester Telegram
Aspire Biopharma Announces Private Placement to Strengthen Finances - TipRanks
Aspire Biopharma Holdings Signs Multiple Material Agreements - TradingView
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R)) - ACCESS Newswire
New Zofran-style powder aims to bring IV-speed nausea relief at home - Stock Titan
Major Financial Concerns Loom as Aspire Biopharma Troubles Deepen - StocksToTrade
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements - ACCESS Newswire
$21M cash boost aims to keep Aspire Biopharma on Nasdaq - Stock Titan
Aspire Biopharma regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Canada
Aspire Biopharma Announces Reverse Stock Split - SouthCoastToday.com
Aspire Biopharma Provides Q3 2025 Business Update - Corpus Christi Caller-Times
Aspire Biopharma regains Nasdaq minimum bid price compliance - MSN
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - Bluefield Daily Telegraph
ASBP Stock Price, Forecast & Analysis | ASPIRE BIOPHARMA HOLDINGS IN (NASDAQ:ASBP) - ChartMill
Aspire Biopharma Holdings files for Series A convertible preferred stock on Nasdaq By Investing.com - Investing.com Nigeria
Aspire Biopharma Holdings files for Series A convertible preferred stock on Nasdaq - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit - ACCESS Newswire
Caffeine you sprinkle under your tongue heads to sports nutrition summit - Stock Titan
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - DelmarvaNow.com
Aspire Biopharma’s Buzz Bomb partners with Blue Shark Beverages - Yahoo Finance
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine C - GuruFocus
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution - Finviz
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of AlprazolamGeneric Xanax(R)for Rapid Anxiety Relief - The Clarion-Ledger
ASBPWAspire Biopharma Holdings Inc Latest Stock News & Market Updates - stocktitan.net
Aspire Biopharma Holdings Inc Azioni (ASBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):